Abstract 48P
Background
Deciphering the role of the adaptive immune system is key to fully realize the potential of immuno-oncology in CCA. TILs are components of the immune microenvironment with a prognostic value across cancer types yet understudied in CCA.
Methods
Tissue blocks from 70 CCA pts undergoing radical surgery between 2013-2023 at the University Hospital of Modena were retrieved. IHC for CD4, CD8 and Foxp3 was performed for the intratumoural (i) and stromal (s) compartment. TILs were recorded as continuous variables and dichotomized to the median. Both bulk RNAseq and spatial trascriptomics were applied through TempO-seq and GeoMx. Correlation analyses and survival models were performed using IBM SPSS Statistics version 25.0.
Results
55% and 42% pts had iCD4+high and sCD4+high CCAs, 54% and 27% of them had iCD8+high and sCD8+high CCAs, and 28% and 34% of them had iFoxp3+high and sFoxp3+high CCAs. iCD4+ high CCAs were associated with pN0 status and a significantly longer RFS than CD4+ low cases (p=0.02). Contrariwise, pts with increased iCD8+ T cell density had significantly shorter RFS than iCD8+ T cells low tumours (p=0.05). iCD4+ T cells together with ECOG PS, nodal status, and adjuvant chemotherapy were independent predictors of outcome. Among iCD4+ high cases, adjuvant chemotherapy significantly prolonged survival compared to observation alone (p=0.01), while no difference was seen within the iCD4+ low subgroup (p=0.06). Compared to CCAs with lower TILs infiltration, iCD4+ high and iCD8+high subsets exhibited 342 and 393 differentially expressed genes, enriched in metabolic, beta-catenin and KRAS pathways and interferon alfa, DNA repair and VEGF networks, respectively.
Conclusions
More than 50% of CCAs displayed high intratumour infiltration of CD4+ and CD8+ TILs, which defined transcriptionally distinct entities with different clinical implications. Interestingly, higher iCD4+ density predicted a favourable prognosis and a benefit from adjuvant chemotherapy in our cohort. These preliminary findings prompt future studies diving into the biomarker potential of TILs in CCA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Azienda Ospedaliero Universitaria di Modena.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1978P - Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA
Presenter: Huiqin Guo
Session: Poster session 13
1979P - Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study
Presenter: Li Zhou
Session: Poster session 13
1980P - Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
Presenter: Evanguelos Xylinas
Session: Poster session 13
1981P - Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
Presenter: Marco Stellato
Session: Poster session 13
1982P - Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Presenter: Begona Perez Valderrama
Session: Poster session 13
1983P - Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 13
1984P - Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
Presenter: Chu Yang
Session: Poster session 13
1985P - Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan
Presenter: Ronac Mamtani
Session: Poster session 13
1986P - Prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ identifies genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next generation sequencing minimal residual disease (MRD) assay
Presenter: Joshua Meeks
Session: Poster session 13
1987P - TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCα pathway
Presenter: Yi Tang
Session: Poster session 13